Almirall Jobs Profile

This profile is a brief introduction for people seeking employment in pharmaceutical graduate jobs, pharmaceutical nurse advisors, pharmaceutical sales jobs, pharmaceutical training jobs, pharmaceutical sales management jobs, pharmaceutical marketing jobs, pharmaceutical executive jobs, or pharmaceutical clinical research associates who may be considering working for Almirall. 

 

Company Overview

 Almirall is a Spanish international pharmaceutical company dedicated to the research, manufacture and distribution of pharmaceutical products in Spain and abroad.
  
As a consolidated international company, Almiral researches, develops and commercialises its own R&D and licensed specialities with the aim of improving the health and quality of life of human beings the world over.
 
Maximum human and economic resources are devoted to constant research into new drugs and into obtaining safe and effective products against discomfort and disease.
 
In order to achieve these objectives, each day the company works on strengthening a corporate culture based on professionalism and teamwork.

This is Almirall's contribution towards helping thousands of people worldwide to keep healthy.

 

Product Overview

The company's principal goal is to provide society with innovative medicines which contribute to improving the health and quality of life of people all over the world.

The following company products are the result of Almirall's Research & Development:

  • almotriptan (anti-migraine drug),
  • ebastine (antihistamine),
  • aceclofenac (anti-inflammatory),
  • almagate (antacid)
  • cinitapride (gastroprocinetic)
  • clebopride (gastroprokinetic)
  • y piketoprofen (anti-inflammatory).


These products are present in over 80 countries, either by Almirall's own marketing or through licensee companies.
 



Claire
Almirall Account Manager
0844 980 8644
(Mon to Fri 0830 to 1800 hours)
claireh@zenopa.com



Please contact the Account Manager for opportunities with this organisation

News

Almirall and Forest complete phase III COPD studies
Laboratorios Almirall and Forest Laboratories have announced the final patients have finished treatment in their phase III Acclaim/COPD I&II (aclidinium clinical trial assessing efficacy and safety in...

Forest, Almirall announce COPD findings
Forest and Almirall have announced positive results in clinical studies of aclidinium bromide in the treatment of chronic obstructive pulmonary disease (COPD).


home | our clients | browse news | browse jobs | hotel directory | copyright © 2008 Zenopa Ltd | terms & conditions of use